Department of Public Health, Osaka City University Graduate School of Medicine.
Research Center for Infectious Disease Sciences, Osaka City University Graduate School of Medicine.
J Epidemiol. 2022 Jan 5;32(1):34-43. doi: 10.2188/jea.JE20210277. Epub 2021 Oct 30.
Since June 2013, Japan has suspended proactive recommendation of human papillomavirus (HPV) vaccination due to self-reported diverse symptoms, including pain and motor dysfunction, as possible serious adverse events following immunization. Although these symptoms may be seen in adolescents without HPV vaccination, their frequency, taking into account disease severity, has not been examined.
A two-stage, descriptive, nationwide epidemiological survey was conducted in 2016, with a 6-month target period from July 1 to December 31, 2015, to estimate the prevalence and incidence of diverse symptoms among Japanese adolescents without HPV vaccination. Participants were 11,037 medical departments in hospitals selected nationwide by stratified random sampling. Eligible patients had to satisfy four criteria: (1) aged 12-18 years upon visiting hospital; (2) having at least one of four symptoms/disorders (pain or sensory dysfunction, motor dysfunction, autonomic dysfunction, or cognitive impairment); (3) symptoms/disorders persisting for at least 3 months; and (4) both criteria (2) and (3) influence attendance at school or work. We then extracted data of patients with diverse symptoms similar to those after HPV vaccination while considering opinions of doctors in charge.
Estimated 6-month period prevalence of diverse symptoms among girls aged 12-18 years without HPV vaccination was 20.2 per 100,000. Annual incidence was estimated to be 7.3 per 100,000.
Adolescent Japanese girls without HPV vaccination also visited hospitals with diverse symptoms similar to those following HPV vaccination. Our findings predict the medical demands for coincident diverse symptoms, which are temporally associated with but not caused by HPV vaccination of Japanese adolescents.
自 2013 年 6 月以来,由于自报告的多种症状,包括疼痛和运动功能障碍,可能是接种疫苗后的严重不良反应,日本暂停了人乳头瘤病毒(HPV)疫苗的主动推荐。尽管这些症状可能在未接种 HPV 疫苗的青少年中出现,但尚未对其频率进行评估,同时考虑到疾病的严重程度。
2016 年进行了一项两阶段、描述性的全国性流行病学调查,目标时间段为 2015 年 7 月 1 日至 12 月 31 日,以估计日本未接种 HPV 疫苗的青少年中多种症状的患病率和发病率。通过分层随机抽样选择全国范围内的 11037 个医疗部门作为参与者。合格的患者必须满足以下四个标准:(1)就诊时年龄为 12-18 岁;(2)至少有以下四种症状/疾病之一(疼痛或感觉功能障碍、运动功能障碍、自主神经功能障碍或认知障碍);(3)症状/疾病持续至少 3 个月;(4)标准(2)和(3)均影响上学或工作。然后,我们在考虑主管医生意见的基础上,提取了与 HPV 疫苗接种后相似的多种症状患者的数据。
估计 12-18 岁未接种 HPV 疫苗的女孩在 6 个月期间的多种症状患病率为每 10 万人中有 20.2 例。估计年发病率为每 10 万人中有 7.3 例。
未接种 HPV 疫苗的日本青少年也因与 HPV 疫苗接种后相似的多种症状就诊。我们的研究结果预测了与日本青少年 HPV 疫苗接种同时发生的多种症状的医疗需求,这些症状与 HPV 疫苗接种有关,但不是由其引起的。